Intercept Pharma (ICPT): AASLD Meeting Takeaway - Needham
- Wall Street again marks new highs in post-election run
- Broadcom Ltd. (AVGO) Tops Q4 EPS by 11c
- Restoration Hardware (RH) Tops Q3 EPS by 4c; Guides Well Below the Street
- Unusual 11 Mid-Day Movers 12/8: (COOL) (TLRD) (DRAM) Higher; (SHIP) (OHRP) (MLSS) Lower
- After-Hours Stock Movers 12/08: (FNSR) (AVGO) (GLPG) Higher; (XTLY) (RH) (DLTH) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Needham & Company analyst, Alan Carr, reiterated his Buy rating on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) after the company presented additional analyses of Ocaliva clinical data as well as preclinical INT-767 data at recent AASLD mtg. Behind Genfit and Intercept, several companies are bringing new candidates forward in NAFLD/ NASH and have begun presenting clinical data.
The analyst believes multiple candidates have an encouraging impact on some histology parameters, but it is too early to tell if any will emerge as viable safe and effective drugs. The analyst stated "we note Intercept and Tobira/ Allergan have shown statistically significant improvements in fibrosis and Gilead recently reported encouraging impact on fibrosis w/ selonsertib. A range of mechanisms are under exploration, including several non-steroidal FXR agonists. Although there were a large number of HCV presentations at the mtg, a shift towards NAFLD/ NASH is increasingly evident."
No change to the price target of $350.
Shares of Intercept Pharmaceuticals closed at $113.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham & Company Reiterates Buy on Ciena (CIEN) Following 4Q Report
- MKM Partners Raises Price Target on Ciena (CIEN) to $30 Following 4Q
- Stifel Reiterates Buy on Casella Waste Systems (CWST) - PT to $16
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesNeedham & Company, Alan Carr
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!